SCHEMBL954029

SCHEMBL954029

CCOC(=O)c1sc(-c2c(C)nn3ccccc23)nc1C1CCOCC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.42
TSHR P16473 2/20 0.42
HSD17B10 Q99714 2/20 0.42
GAA P10253 1/20 0.42
HTT P42858 1/20 0.42
DHODH Q02127 3/20 0.40
LMNA P02545 1/20 0.38
CDC7 O00311 3/20 0.38
DBF4 Q9UBU7 3/20 0.38
TRPM8 Q7Z2W7 1/20 0.38
KDM4E B2RXH2 2/20 0.37
CASP3 P42574 1/20 0.36
CHEK1 O14757 1/20 0.36
ATR Q13535 1/20 0.36
PDCD1 Q15116 1/20 0.36
ATRIP Q8WXE1 1/20 0.36
CD274 Q9NZQ7 1/20 0.36
OGFRL1 Q5TC84 1/20 0.35
NPC1 O15118 1/20 0.35
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL953767 0.91 TSHR (0.43) ALDH1A1TSHRHSD17B10GAAHTT
SCHEMBL952323 0.88 CNR1 (0.39) TSHRKDM4ECHEK1ATRPDCD1
SCHEMBL953761 0.87 CHEK1 (0.36) TSHRLMNACHEK1ATRPDCD1
SCHEMBL953769 0.81 CDC7 (0.59) ALDH1A1LMNACDC7DBF4TRPM8
SCHEMBL952685 0.79 LMNA (0.46) ALDH1A1HSD17B10LMNACDC7DBF4
SCHEMBL957422 0.78 CDC7 (0.59) ALDH1A1HSD17B10DHODHCDC7DBF4
SCHEMBL955453 0.78 TSHR (0.42) ALDH1A1TSHRHSD17B10HTTLMNA
SCHEMBL953958 0.78 TSHR (0.42) ALDH1A1TSHRHSD17B10HTTLMNA
SCHEMBL952070 0.78 CDC7 (0.47) ALDH1A1TSHRLMNACDC7DBF4
SCHEMBL953687 0.75 CDC7 (0.61) ALDH1A1HSD17B10HTTDHODHLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9139589-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-09-22 US disclosed
US-9090601-B2 Thiazole derivatives MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-07-28 US disclosed
EP-2391619-A1 HETEROARYLS AND THEIR USE AS PI3K INHIBITORS Millennium Pharmaceuticals, Inc. (US) 2011-12-07 EP disclosed
US-20110003807-A1 Thiazole derivatives MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
US-20110003806-A1 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
WO-2010090716-A1 HETEROARYLS AND THEIR USE AS PI3K INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003807-A1 Thiazole derivatives MTOR, RICTOR, AKT2 ALDH1A1 1687/4885TSHR 1608/4885HSD17B10 763/4885
US-20110003806-A1 Heteroaryls and uses thereof RICTOR, MTOR, AKT1S1 ALDH1A1 728/4885TSHR 2433/4885HSD17B10 163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.